Sanggenon C

SKU: orb1689928

Description

Sanggenon C is a natural flavanone Diels-Alder adduct with demonstrated anti-inflammatory and antioxidant properties. Research applications include in vitro studies on NF-κB signaling, nitric oxide production in macrophages, and pancreatic lipase inhibition, relevant for metabolic and inflammatory disease research.

Research Area

Cell Biology, Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 80651-76-9
• MW: 708.71
• Purity: 99.76% (May vary between batches)
• Formula: C₄₀H₃₆O₁₂
• SMILES: CC(C)=CC[C@]12Oc3cc(O)c([C@H]4C=C(C)C[C@@H]([C@H]4C(=O)c4ccc(O)cc4O)c4ccc(O)cc4O)c(O)c3C(=O)[C@@]1(O)Oc1cc(O)ccc21
• Target: Apoptosis,Phosphatase,ERK,NF-κB
• Solubility: DMSO:150 mg/mL (211.65 mM)

Bioactivity

• In Vivo:
  METHODS: Mice were intraperitoneally injected with Sanggennaon C (10 mg, 20 mg/kg/day) for 3 weeks. Four weeks after surgery, the hearts, lungs, and tibiae of the mice were dissected and weighed or measured, and the heart weight (HW)/body weight (BW) (mg/g), HW/tibia length (TL) (mg/mm), and lung weight (LW)/BW (mg/g) ratios were compared among the different groups. RESULTS Sanggennaon C treatment prevented the development of ventricular dysfunction, such as decreased left ventricular end-diastolic diameter, left ventricular end-systolic diameter, and increased LVFS and LVEF; Sanggennaon C-treated mice showed attenuated cardiac hypertrophy, such as decreased CSA, and reduced HW/BW and HW/TL ratios.
• In Vitro:
  METHODS: Appropriate concentrations of Sanggenon C (10 and 20 μM) were administered to U-87MG and LN-229, as well as dimethyl sulfoxide (DMSO) as a control, for 48 hours. Cell viability was determined by MTT assay. RESULTS Sanggenon C inhibited the cell proliferation of GBM cell lines U-87 MG and LN-229 in a concentration-dependent manner. METHODS: U-87 MG and LN-229 cells were treated with Sanggenon C (10 μM), cell apoptosis was detected by flow cytometry, and the expression levels of related proteins were analyzed by Western blot. RESULTS Silencing of DAPK1 reduced Sanggenon C-induced cell apoptosis. Western blot analysis further showed that in GBM cells treated with Sanggenon C, the protein levels of C-PARP and C-Caspase3 were reduced by silencing DAPK1. METHODS: Human colon cancer cell line (HT-29) was treated with Sanggenon C (0, 5, 10, 20, 40 and 80 μM) for 0, 12, 24, 48 or 72 h. As a measure of intracellular ROS and ATP, the production of NO in cells was measured by the Griess method according to the instructions of the NO detection kit. RESULTS Sanggenon C can increase the level of intracellular ROS in human colon cancer cells, and this accumulation is enhanced when the dose is increased; Sanggenon C can interfere with the level of intracellular ROS; Sanggenon C can interfere with and increase the levels of intracellular Ca2+ and ATP, both in a time-dependent manner, and this accumulation is enhanced when the dose is increased; Sanggenon C can significantly interfere with and inhibit the production of NO in a dose- and time-dependent manner.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NF-kB, NFkB, Nuclear factor-κB, Nuclear factor-kappaB, NFκB, NF-κB, inhibit, Inhibitor, Sanggenone C, Sanggenon C

Compound Identifiers

PubChem CID

15479638